Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis

Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I56-60. doi: 10.1136/ard.58.2008.i56.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / physiopathology*
  • Arthritis, Rheumatoid / therapy*
  • Cytokines / biosynthesis
  • Humans
  • Infliximab
  • Neovascularization, Pathologic / physiopathology
  • Tumor Necrosis Factor-alpha / immunology*
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Cytokines
  • Tumor Necrosis Factor-alpha
  • Infliximab